GlassScriptPhysician profile
Candice P Jantz
NPI 1023227717
$14,051.40
in general payments reported to CMS, 2019-2025
46 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $1,386 · 2021: $2,092 · 2022: $2,000 · 2023: $1,502 · 2024: $2,252 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,463 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,462.91 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,309.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,348.14 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,255.74 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $785.45 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $556.01 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $347.32 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Pfizer INC. | $318.48 | 2019-2025 | |
| Celgene Corporation | $269.04 | 2021-2024 | Zeposia |
| Vivus LLC | $251.19 | 2021-2025 | Qsymia, Pancreaze |
| Ironwood Pharmaceuticals, INC | $242.51 | 2019-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $225.50 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $219.87 | 2024-2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $215.33 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $189.93 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $180.17 | 2020-2023 | Talicia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $174.38 | 2022-2025 | |
| Gilead Sciences, INC. | $163.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $157.72 | 2024-2025 | Dupixent |
| Romark Laboratories, Lc | $151.65 | 2019-2020 | |
| Ardelyx, INC. | $148.85 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $144.99 | 2019-2021 | |
| Novo Nordisk INC | $137.14 | 2025 | Wegovy |
| Organon LLC | $131.41 | 2023-2025 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $118.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Alfasigma USA, INC. | $102.93 | 2020 | |
| Allergan, INC. | $95.35 | 2019-2020 | |
| Evoke Pharma, INC. | $84.43 | 2022-2023 | Gimoti |
| Daiichi Sankyo INC. | $83.18 | 2019-2021 | |
| Braintree Laboratories, INC. | $80.00 | 2020-2024 | Suflave, Sutab |
| Ucb, INC. | $71.88 | 2019-2020 | |
| Lilly USA, LLC | $57.21 | 2025 | Omvoh |
| Neuraxis, INC. | $52.90 | 2025 | |
| Perspectum Diagnostics LTD | $48.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.74 | 2022-2023 | Oxlumo |
| Shionogi INC | $42.36 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $39.92 | 2024-2025 | Iqirvo, Bylvay |
| Laborie Medical Technologies Corp. | $39.12 | 2024 | Renovarp |
| Abbott Laboratories | $29.72 | 2019 | |
| Medtronic, INC. | $29.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.31 | 2023 | Cyltezo |
| Mirum Pharmaceuticals, INC. | $18.36 | 2025 | Livmarli |
| Shire North American Group INC | $17.79 | 2019 | |
| Ethicon US, LLC | $17.58 | 2019 | |
| Celltrion USA INC. | $14.79 | 2024 | Zymfentra |
| Enterra Medical, INC. | $13.30 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,142.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Jantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.